Fate Therapeutics Inc (FATE)
3.68
+0.23
(+6.67%)
USD |
NASDAQ |
May 31, 16:00
3.70
+0.02
(+0.54%)
After-Hours: 20:00
Fate Therapeutics Revenue (Quarterly): 1.925M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 1.925M |
December 31, 2023 | 1.676M |
September 30, 2023 | 1.944M |
June 30, 2023 | 0.933M |
March 31, 2023 | 58.98M |
December 31, 2022 | 44.36M |
September 30, 2022 | 14.98M |
June 30, 2022 | 18.55M |
March 31, 2022 | 18.41M |
December 31, 2021 | 17.07M |
September 30, 2021 | 14.22M |
June 30, 2021 | 13.41M |
March 31, 2021 | 11.14M |
December 31, 2020 | 15.90M |
September 30, 2020 | 7.558M |
June 30, 2020 | 5.465M |
March 31, 2020 | 2.515M |
December 31, 2019 | 2.802M |
September 30, 2019 | 2.429M |
June 30, 2019 | 2.817M |
March 31, 2019 | 2.632M |
December 31, 2018 | 1.661M |
September 30, 2018 | 1.026M |
June 30, 2018 | 1.027M |
Date | Value |
---|---|
March 31, 2018 | 1.026M |
December 31, 2017 | 1.027M |
September 30, 2017 | 1.026M |
June 30, 2017 | 1.026M |
March 31, 2017 | 1.027M |
December 31, 2016 | 1.027M |
September 30, 2016 | 1.026M |
June 30, 2016 | 1.027M |
March 31, 2016 | 1.322M |
December 31, 2015 | 1.076M |
September 30, 2015 | 1.026M |
June 30, 2015 | 0.329M |
March 31, 2015 | |
December 31, 2014 | |
September 30, 2014 | |
June 30, 2014 | |
March 31, 2014 | |
December 31, 2013 | |
September 30, 2013 | 0.209M |
June 30, 2013 | 0.29M |
March 31, 2013 | 0.472M |
December 31, 2012 | 0.643M |
September 30, 2012 | 0.528M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.933M
Minimum
Jun 2023
58.98M
Maximum
Mar 2023
12.85M
Average
9.35M
Median
Revenue (Quarterly) Benchmarks
Amicus Therapeutics Inc | 110.40M |
Ocular Therapeutix Inc | 14.77M |
Alpine Immune Sciences Inc (DELISTED) | 7.032M |
AnaptysBio Inc | 7.179M |
Stoke Therapeutics Inc | 4.216M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -48.00M |
Total Expenses (Quarterly) | 52.99M |
EPS Diluted (Quarterly) | -0.47 |
Enterprise Value | 35.36M |
Profit Margin (Quarterly) | -2.49K% |
Earnings Yield | -52.17% |
Normalized Earnings Yield | -52.17 |